Bionano Genomics, Inc. (BNGO) has a negative trailing P/E of -0.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 5.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -419.70%, forward earnings yield 17.36%.
Criteria proven by this page:
Overall SharesGrow Score: 47/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2017 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2018 | 0.0 | 0.00 | 0.06 | 0.05 | - |
| 2019 | 0.0 | 0.00 | 0.09 | 0.03 | - |
| 2020 | -8.0 | 0.10 | 9.34 | 38.52 | - |
| 2021 | -11.7 | 0.12 | 2.50 | 46.95 | - |
| 2022 | -3.2 | -0.05 | 1.73 | 15.49 | - |
| 2023 | -0.3 | -0.01 | 0.68 | 1.82 | - |
| 2024 | -0.3 | 0.00 | 0.93 | 1.07 | - |
| 2025 | -0.3 | 0.00 | 0.19 | 0.29 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $0.00 | $6.79M | $-18.85M | -277.5% |
| 2017 | $0.00 | $9.51M | $-23.37M | -245.8% |
| 2018 | $-1,568.16 | $12M | $-18.5M | -154.1% |
| 2019 | $-1,194.37 | $10.13M | $-29.84M | -294.5% |
| 2020 | $-236.58 | $8.5M | $-41.14M | -483.8% |
| 2021 | $-157.02 | $17.98M | $-72.44M | -402.8% |
| 2022 | $-275.09 | $27.8M | $-132.6M | -476.9% |
| 2023 | $-408.60 | $36.12M | $-232.49M | -643.7% |
| 2024 | $-60.05 | $30.78M | $-112.02M | -364% |
| 2025 | $-4.85 | $28.51M | $-26.4M | -92.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.56 | $-2.56 – $-2.56 | $34.55M | $34.55M – $34.55M | 1 |
| 2027 | $-1.02 | $-1.02 – $-1.02 | $46.54M | $46.54M – $46.54M | 1 |
| 2028 | $-0.49 | $-0.49 – $-0.49 | $58.77M | $56.52M – $61.02M | 1 |
| 2029 | $-0.15 | $-0.15 – $-0.15 | $71.82M | $71.82M – $71.82M | 1 |
| 2030 | $0.36 | $0.36 – $0.36 | $87.61M | $87.61M – $87.61M | 1 |
